Table 1. Baseline Characteristics by Smoking Status at 24-Week Follow-up.
| Characteristic | Participants, No. (%) | ||
|---|---|---|---|
| Whole cohort (N = 4260) | Continued smoking (n = 3781) | Stopped smoking (n = 479) | |
| Age, y | |||
| 18-30 | 573 (13.5) | 528 (14.0) | 45 (9.4) |
| 31-40 | 752 (17.7) | 677 (17.9) | 75 (15.7) |
| 41-50 | 1129 (26.5) | 1008 (26.7) | 121 (25.3) |
| 51-60 | 1244 (29.2) | 1096 (29.0) | 148 (30.9) |
| 61-75 | 562 (13.2) | 472 (12.5) | 90 (18.8) |
| Sex | |||
| Male | 1775 (41.7) | 1577 (41.7) | 198 (41.3) |
| Female | 2485 (58.3) | 2204 (58.3) | 281 (58.7) |
| Race | |||
| White | 3044 (71.5) | 2662 (70.4) | 382 (79.7) |
| Black | 1065 (25.0) | 990 (26.2) | 75 (15.7) |
| Asian | 32 (0.8) | 27 (0.7) | 5 (1.0) |
| Othera | 119 (2.8) | 102 (2.7) | 17 (3.5) |
| Body mass index groupb | |||
| <18.5 | 63 (1.5) | 58 (1.5) | 5 (1.0) |
| 18.5 to <25 | 1054 (24.7) | 951 (25.2) | 103 (21.5) |
| 25 to <30 | 1373 (32.2) | 1203 (31.8) | 170 (35.5) |
| >30 | 1731 (40.6) | 1535 (40.6) | 196 (40.9) |
| Psychiatric history | 2359 (55.4) | 2106 (55.7) | 253 (52.8) |
| Current use of psychotropic medication | 923 (21.7) | 852 (22.5) | 71 (14.8) |
| Diabetes | 300 (7.0) | 264 (7.0) | 36 (7.5) |
| Evidence of cardiovascular disease | 201 (4.7) | 180 (4.8) | 21 (4.4) |
| Randomized treatment group | |||
| Bupropion | 1067 (25.0) | 945 (25.0) | 122 (25.5) |
| Nicotine replacement therapy | 1062 (24.9) | 949 (25.1) | 113 (23.6) |
| Placebo | 1065 (25.0) | 993 (26.3) | 72 (15.0) |
| Varenicline | 1066 (25.0) | 894 (23.6) | 172 (35.9) |
| Baseline scores, mean (SD) | |||
| Nicotine dependence | 5.71 (1.93) | 5.77 (1.91) | 5.23 (2.02) |
| Depression | 2.44 (2.91) | 2.47 (2.93) | 2.22 (2.80) |
| Anxiety | 4.25 (3.68) | 4.30 (3.61) | 3.85 (3.44) |
a
Information on breakdown of subcategories included is unavailable.
b
Body mass index is calculated as weight in kilograms divided by height in meters squared.